Seer (NASDAQ:SEER) Releases Earnings Results

Seer (NASDAQ:SEER) announced its quarterly earnings data on Tuesday. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01, FiscalAI reports. The company had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.15 million. Seer had a negative return on equity of 26.21% and a negative net margin of 450.86%.

Here are the key takeaways from Seer’s conference call:

• Seer cut its 2026 revenue outlook to $13.5 million–$14.5 million from $16 million–$18 million. Management attributed the reduction to constrained academic and government funding, longer purchasing cycles, and customer uncertainty during the activist campaign and acquisition proposals.
• Third-quarter revenue rose sequentially to $4.0 million from $3.1 million, with increased instrument shipments and new customer agreements; established customers continued to buy consumables. Management said sales cycles have shortened to about six months, though repeat purchases remain project-driven and pull-through was flat sequentially.
• Seer highlighted growing scientific validation for Proteograph, including 116 publications and population-scale research demonstrating deep protein coverage. The company also cited new large biopharma adopters and AI-focused research as potential sources of future demand, but did not quantify their revenue contribution.
• Seer ended the quarter with approximately $198 million in cash, cash equivalents, and investments, while operating expenses fell to $16.5 million from $21.5 million a year earlier and net loss narrowed to $13.7 million. Management said its capital is sufficient to reach cash-flow breakeven under its operating plan, which depends on revenue growth and improved gross margins.

Seer Stock Performance

NASDAQ:SEER opened at $1.59 on Thursday. The company has a 50-day moving average of $1.95 and a 200-day moving average of $1.91. Seer has a 52 week low of $1.55 and a 52 week high of $2.38. The company has a market capitalization of $88.04 million, a price-to-earnings ratio of -1.38 and a beta of 1.49.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $4.00.

About Seer

Seer, Inc. is a life sciences company that develops technologies for large-scale protein analysis, known as proteomics. The company’s platform is designed to help researchers study a broad range of proteins in biological samples and generate detailed information that may support drug discovery, disease research and biomarker development. Seer’s primary offering is the Proteograph Product Suite, which combines engineered nanoparticle technology, laboratory consumables, automation and software. The system is intended to provide deep, unbiased proteomic analysis from relatively small biological samples, including blood and other complex specimens.